Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulevirtide with Pegylated Interferon Alfa-2a for Chronic Hepatitis Delta
NCT03852433Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of bulevirtide in hepatitis D (HDV), sponsored by Gilead Sciences. Started May 2019; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT03852433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852433.